134P Safety and efficacy of multi-target TKI combined with nivolumab in checkpoint inhibitor-refractory advanced NSCLC patients: A prospective, single arm, two stage study

Han, Bei; Zhang, B.; Zhong, H.; Shi, C.; Gao, Z.; Zhong, R.; Gu, A.; Chu, T.; Wang, H.; Xiong, L.; Zhang, W.; Zhang, Xinyu; Yan, B.; Teng, J.; Wang, W.; Bai, H.; R., Qiao,; Cheng, L.; Kuang, Y.

doi:10.1016/j.iotech.2022.100246

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the exploration of NSCLC treatment after failure of previous ICIs is still ongoing, clinical results continued to be published after our search deadline [ 33 ]. For the sake of data credibility, we only included the RCTs, and excluded many retrospective studies, such as our previous international multi-center retrospective study by Auclin E [ 30 ] and the study on ramucirumab combined with docetaxel by Dawar, R [ 34 ], the study on immunotherapy versus chemotherapy plus immunotherapy by William P. Tompkins [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials

Wang,

Fu,

Sun

et al. 2024

BMC Immunol

View full text Add to dashboard Cite

Background Although immune checkpoint inhibitors (ICIs) have brought survival benefits to non-small cell lung cancer (NSCLC), disease progression still occurs, and there is no consensus on the treatment options for these patients. We designed a network meta-analysis (NMA) to evaluate systemic treatment options for NSCLC after failure of ICIs. Methods PubMed, Embase, Web of Science and Cochrane Library databases were searched, then literature screening was followed by NMA. We included all Phase II and III randomized controlled trials (RCTs). Progression-free survival (PFS) and overall survival (OS) used hazard ratio (HR) for evaluation. Objective response rate (ORR) and adverse events (AEs) used odds ratio (OR) and relative risk (RR) effect sizes, respectively. R software was applied to compare the Bayesian NMA results. Results We finally included 6 studies. 1322 patients received ICI plus Chemotherapy (ICI + Chemo), ICI plus Anti-angiogenic monoclonal antibody (ICI + Antiangio-Ab), ICI plus Tyrosine kinase inhibitor (ICI + TKI), Tyrosine kinase inhibitor plus Chemotherapy (TKI + Chemo), Standard of Care (SOC), Chemotherapy (Chemo). TKI + Chemo is associated with longer PFS, higher ORR (surface under cumulative ranking curve [SUCRA], 99.7%, 88.2%), ICI + TKI achieved the longest OS (SUCRA, 82.7%). ICI + Antiangio-Ab was granted the highest safety rating for adverse events (AEs) of any grade, AEs greater than or equal to grade 3 and AEs of any grade leading to discontinuation of treatment (SUCRA, 95%, 82%, 93%). Conclusions For NSCLC after failure of ICIs, TKI + Chemo was associated with longer PFS and higher ORR, while ICI + TKI was associated with the longest OS. In terms of safety, ICI + Antiangio-Ab was the highest.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials

Wang,

Fu,

Sun

et al. 2024

BMC Immunol

View full text Add to dashboard Cite

show abstract

“…In order to fight the issue of primary resistance, a significant amount of work has gone into designing combination approaches, typically with empiric complementary drugs. For instance, ICIs, multi-target TKIs, and EGFR inhibitors have all been used in conjunction with chemotherapy in the treatment of lung, breast, stomach, and renal cell carcinoma [ 111 ]. Additionally, a systematic search for biomarkers that can anticipate the initial ICI response has been conducted.…”

Section: Introductionmentioning

confidence: 99%

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

et al. 2023

View full text Add to dashboard Cite

Cancer is still the leading cause of death globally. The approval of the therapeutic use of monoclonal antibodies against immune checkpoint molecules, notably those that target the proteins PD-1 and PD-L1, has changed the landscape of cancer treatment. In particular, first-line PD-1/PD-L1 inhibitor drugs are increasingly common for the treatment of metastatic cancer, significantly prolonging patient survival. Despite the benefits brought by immune checkpoint inhibitors (ICIs)-based therapy, the majority of patients had their diseases worsen following a promising initial response. To increase the effectiveness of ICIs and advance our understanding of the mechanisms causing cancer resistance, it is crucial to find new, effective, and tolerable combination treatments. In this article, we addressed the potential of ICIs for the treatment of solid tumors and offer some insight into the molecular pathways behind therapeutic resistance to ICIs. We also discuss cutting-edge therapeutic methods for reactivating T-cell responsiveness after resistance has been established.

show abstract

134P Safety and efficacy of multi-target TKI combined with nivolumab in checkpoint inhibitor-refractory advanced NSCLC patients: A prospective, single arm, two stage study

Cited by 2 publications

References 0 publications

Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials

Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Contact Info

Product

Resources

About